Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

3714 - Head and Neck (HN) Primary Sarcomatoid Carcinoma (PSC) profile by High-throughput somatic mutation profiling.

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Vincent Fallet

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

V. Fallet1, R. Taouachi2, R. Saffroy3, A. Ben Lakhdar4, N. Rabbe5, F. André6, S. Temam7, A. Lemoine3, M. Wislez1

Author affiliations

  • 1 Thoracic Oncology, APHP, CancerEst, Tenon University Hospital / GRC-04 Theranoscan, Sorbonne Universités, UPMC Université Paris 06, 75020 - Paris/FR
  • 2 Department Of Surgery, Institut Curie, PSL Research University, Saint Cloud/FR
  • 3 Department Of Biochiemistry And Oncogenetics, AP-HP, GH Paris-Sud, Hôpital Paul Brousse / Platform Oncomolpath/INCA, Villejuif/FR
  • 4 Pathology, Gustave Roussy Institute, 94805 - Villejuif/FR
  • 5 Grc N°04, Theranoscan, APHP, CancerEst, Tenon University Hospital, 75020 - Paris/FR
  • 6 Breast Cancer Unit, Department Of Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 7 Department Of Head And Neck Surgery, Institut Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 3714

Background

The Head & Neck Primary Sarcomatoid Carcinoma (HN PSC) is a rare sub-type of squamous cell carcinoma with poor prognosis. This study sought to describe the mutational profile of HN PSC using high-throughput genotyping technology Massarray, (Agena, Hamburg).

Methods

We included 45 patients with HN PSC. We used PCR mass spectrometry detection to establish the DNA mutation profiles of 72 samples from these patients (45 primary tumors, 5 metastatic cervical nodes and 22 non tumoral tissues) studying 214 mutations affecting 26 oncogenes and tumor suppressor genes.

Results

In total, 33/45 (77.3%) patients were male and 31/45 (69%) were smokers. Median age was 60 years (range 13 – 93 years) and 28/45 (62.2%) were metastatic. The main tumor sites were oral cavities (31.1%) and larynx (28.1%). The predominant histological subtype was the pleomorphic form (66,7%). In the 72 tumors, 18 distinct somatic alterations were identified, 15 tumors (33%) harboring at least one mutation. The most frequent mutations were TP53 (11.1%), PIK3CA (8.9%), EPHA5 (4.4%), MET (4.4%), NOTCH1 (4.9%), NTRK2 (2.2%), BRAF (2.2%), JAK2 (2,2%), KRAS (2,2%) and NRF2 (2,2%). The presence of a mutation was not correlated with any clinical characteristic (age, sex, primary located site, cancer stage, tobacco and alcohol status). Only 1/45 (2.2%) tumor presented a targetable mutation with tyrosine kinase inhibitor (mutation BRAF). The mutational profile was identical between the local tumor site and the cervical node in 4/5 patients.

Conclusions

Our results demonstrated that HN PSC had a similar mutational profile of other HN carcinoma such as TP53, PIK3CA and NOTCH1 mutations. It reinforced the hypothesis of a single cell clone, which is acquired with different histological phenotypes by different, still unknown mechanisms involving epithelial to mesenchymal transition.

Clinical trial identification

Legal entity responsible for the study

Marie Wislez.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

V. Fallet: Travel, accommodations, expenses: GSK, BMS, Novartis, Boeringher Ingelheim. M. Wislez: Research funding: BMS, Boehringer Ingelheim; Consulting or advisory role: AstraZeneca, Roche, BMS, MSD, Novartis, Boehringer Ingelheim. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings